Preoperative management of spontaneous cerebrospinal fluid rhinorrhea with acetazolamide.
Ashwini Milind TilakHeather KoehnJosé MattosSpencer C PaynePublished in: International forum of allergy & rhinology (2018)
This is the first study to report the use of acetazolamide therapy as a primary treatment option for spontaneous CSF rhinorrhea. This therapy enabled surgery to be avoided in 31.3% of patients. This would indicate that in the absence of other contraindications for delaying repair, a trial of acetazolamide therapy could be considered as an initial option in the management of isolated spontaneous CSF rhinorrhea.
Keyphrases
- cerebrospinal fluid
- end stage renal disease
- ejection fraction
- clinical trial
- chronic kidney disease
- study protocol
- newly diagnosed
- patients undergoing
- peritoneal dialysis
- randomized controlled trial
- prognostic factors
- stem cells
- coronary artery disease
- mesenchymal stem cells
- acute coronary syndrome
- replacement therapy
- placebo controlled